Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of Suzetrigine Tablet Formulations
NCT06336096Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of suzetrigine in pain (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration at Day 43, Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration at Day 43 and 1 more. Started Mar 2024; status: completed.
02
Drugs
suzetrigine
03
Conditions
pain
Beyond the preview
Go deeper on NCT06336096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06336096.